EpimAb Biotherapeutics
Latest round
- Series C
Last raised
- Jun 2021
Total raised
- $220M
Investors
- 15
About EpimAb Biotherapeutics
, operates as a biopharmaceutical company that develops bi-specific antibodies therapeutics. The company was founded by Chengbin Wu is the founder of EpimAb Biotherapeutics and he was the Senior VP Biologics at Shanghai ChemPartner. Before that he was a Volwiler Associate Fellow at Abbott laboratories, USA. In March 2021, EpimAb Biotherapeutics, Inc. EpimAb Biotherapeutics, Inc. engages in providing research and development via FIT-Ig (Fabs-In-Tandem) technology, which is based on the scientific rationale to combine the functions of two parental antibodies into one single molecule. This is achieved by re-arranging the DNA sequences of two monoclonal antibodies into three constructs and co-expressing them in mammalian cells. The products pipelines of the company include EMB-01, EMB-06, EMB-09,and can be used in oncology immunity field. EpimAb Biotherapeutics, Inc.
Who invested in EpimAb Biotherapeutics
15 investors across 4 rounds
See all investors in EpimAb Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about EpimAb Biotherapeutics
Who invested in EpimAb Biotherapeutics?
EpimAb Biotherapeutics has 15 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has EpimAb Biotherapeutics raised?
EpimAb Biotherapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did EpimAb Biotherapeutics last raise money?
EpimAb Biotherapeutics's most recent round on record is a Series C, in Jun 2021.
What does EpimAb Biotherapeutics do?
, operates as a biopharmaceutical company that develops bi-specific antibodies therapeutics.
Where is EpimAb Biotherapeutics headquartered?
EpimAb Biotherapeutics is headquartered in Shanghai, China.
Which VCs invest in companies like EpimAb Biotherapeutics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at EpimAb Biotherapeutics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like EpimAb Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.